Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 4/20 | 0.41 |
| ▸ | AHCY | P23526 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7011732 | 0.89 | F10 (0.40) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7010527 | 0.78 | STS (0.49) | MEN1KMT2ASMN1; SMN2STSGPR119 | |
| SCHEMBL7018813 | 0.73 | PYGL (0.47) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3379626 | 0.70 | MEN1 (0.64) | MEN1KMT2ASMN1; SMN2STSGPR119 | |
| SCHEMBL25388020 | 0.70 | MEN1 (0.53) | MEN1KMT2ASTSGPR119USP30 | |
| SCHEMBL25391302 | 0.70 | MEN1 (0.67) | MEN1KMT2ASTSGPR119USP30 | |
| SCHEMBL7014449 | 0.70 | ALOX5 (0.58) | MEN1KMT2A | |
| SCHEMBL7018810 | 0.70 | KMT2A (0.44) | MEN1KMT2ASTS | |
| SCHEMBL25390400 | 0.69 | MEN1 (0.50) | MEN1KMT2ASTSGPR119 | |
| SCHEMBL2797073 | 0.69 | STS (0.57) | MEN1KMT2ASTSGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1302462-A1 | SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | SULT1E1, RRS1, SHH | MEN1 1401/4885KMT2A 636/4885SMN1; SMN2 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.